Torrent Pharma enters into exclusive licensing agreement with Reliance Life Sciences

26 Dec 2014 Evaluate

Torrent Pharmaceuticals has entered into an exclusive licensing agreement with Reliance Life Sciences for marketing 3 biosimilars in India - Rituximab, Adalimumab and Cetuximab. As per the agreement, Reliance Life Sciences will develop and supply these products to Torrent Pharma after obtaining all necessary regulatory approvals. Torrent Pharma will be the only company to market these biosimilars in India other than Reliance Life Sciences. Reliance Life Sciences will manufacture these products at its facility in Navi Mumbai and supply to Torrent Pharma for a period of ten years.

Torrent Pharma forayed into the oncology and dermatology segments in 2011-12 with the launch of exclusive divisions and has since gained a strong position in these segments. The licensing agreement with Reliance Life Sciences is expected to significantly boost its presence in these segments in the coming years.

Rituximab and Cetuximab cater to the oncology segment and are used in the treatment of various cancers like leukemia, lymphoma, colorectal, head and neck cancers. Adalimumab is the most preferred therapy for the treatment of auto immune disorders like rheumatoid arthritis, psoriasis and IBD.

Torrent Pharma Share Price

3853.85 33.40 (0.87%)
31-Dec-2025 15:17 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1719.60
Dr. Reddys Lab 1271.50
Cipla 1512.05
Zydus Lifesciences 914.90
Lupin 2108.90
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×